Clincial management of breast cancer with proven BRCA 1, BRCA 2 or TP53 mutation

In the UK, breast cancer is the most common cancer. 5-10% of all breast cancers are caused by genetic mutations. Genetic mutation such as BRCA1/2 and TP53 mutation is associated with 20-25% of hereditary breast cancers. Early genetic diagnosis allows patients to choose between different cancer prevention options. This includes a daily tablet and/or annual radiological imaging or even preventative radical breast/ovarian surgery. Despite the availability of national guidelines, the clinical management of patients in Tayside is unclear, poorly documented and followed-up. This project aims to establish the clinical management details of these patients and contribute to service improvements.